Results 181 to 190 of about 282,772 (364)

A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High‐Concentration, Long‐Acting Cabotegravir Formulation in Adults Without HIV

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting (LA) cabotegravir 200‐mg/mL (CAB200) injections are approved for HIV‐1 prevention and as a complete LA HIV‐1 treatment regimen with rilpivirine. A high‐concentration suspension formulation, cabotegravir 400 mg/mL (CAB400‐D), was developed to enable less frequent dosing and self‐administration. This phase 1, double‐blind, randomized
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick‐Sanders, Randa Hareedy, Louise Harkness, Claudia Leemereise, Kjersten Offenbecker, Christina Donatti, Darin B. Brimhall, Christian Schwabe, Craig Boyle, Michael A. Hassman, Steve Knowles, Ronald D'Amico, William R. Spreen   +16 more
wiley   +1 more source

Can Bilirubin Be An Indicator For Predicting Coronary Artery Disease?

پیاورد سلامت, 2013
Background and Aim: Oxidative interactions such as the formation of oxygen, peroxy radicals and LDL-cholesterol oxidation are involved in the development of atherosclerosis process This study aims to examine the relationship between serum bilirubin ...
Fariba Nabatchian, Nahid Einollahi, Mohammad Ali Boroomand, Sakineh Abbasi   +3 more
doaj  

Studies on Bile Pigments (I). On the Nature of Indirect and Direct Bilirubin

, 1951
Kenzi YAMAOKA, Kiyowo Kosaka
openalex   +2 more sources

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

Clinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak, Barbara Yang, Briohny A. Johnston, Sudha Parasuraman, Kushal J. Paneliya, Virna Schuck   +9 more
wiley   +1 more source

Bilirubin metabolism [PDF]

Molecular Aspects of Medicine, 1963
openaire   +2 more sources

Open‐Chain Tetrapyrroles Meet Metal Ions in the Functional Molecular Material Science

ChemPlusChem, EarlyView.
Open‐chain tetrapyrroles, synthesized via oxidative cleavage and condensation, offer greater structural flexibility than cyclic counterparts like porphyrins. Their tunable electronic and geometric properties through metalation enable applications in bioimaging, therapies, ion sensing, chiroptical materials, and spintronic devices, making them valuable ...
Aninda Ghosh, Sandipa Bhandari, Hiroyuki Furuta, Masatoshi Ishida   +3 more
wiley   +1 more source

The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. [PDF]

, 1968
R Tenhunen, Harvey S. Marver, R. Schmid
openalex   +1 more source

Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration

Clinical Pharmacology &Therapeutics, EarlyView.
Atazanavir has been reported to increase total serum bilirubin level up to ninefold. It is widely believed that the observed total bilirubin elevation is primarily due to UGT1A1 inhibition. However, UGT enzymes are well‐known as a low‐affinity and high‐capacity system, and the observed drug–drug interaction mediated by UGTs is usually less than twofold.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Two hepatic cytoplasmic protein fractions, Y and Z, and their possible role in the hepatic uptake of bilirubin, sulfobromophthalein, and other anions [PDF]

, 1969
A J Levi, I. M. Arias
openalex   +1 more source